Can Thrombin Generation Measurement Predict the Risk of Venous Thromboembolism in Acute Ill Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01744431|
Recruitment Status : Completed
First Posted : December 6, 2012
Last Update Posted : December 16, 2015
Can thrombin generation measurement predict the risk of venous thromboembolism in acute ill patients
Traditional coagulation tests do not assess the whole coagulation system. Thrombin generation assays measure the ability of plasma sample to generate thrombin following in vitro activation of coagulation. In contrast to the classical clotting assays, thrombin generation reflects and integrates all pro and anticoagulant reactions that regulate the formation and inhibition of thrombin.
The aim of our study is to investigate whether thrombin generation would be able to predict a hypercoagulable state in acute ill patients admitted in the internal medical departments and how it correlates with the Padua prediction score, a score that could assists the risk for venous thromboembolism in hospitalized medical patients.
In total 300 patients are planned for inclusion in this trial. After signing an informed consent a blood sample will be obtained from each participant. We will measure the thrombin generation over time in plasma assessed by the calibrated automated thrombogram (CAT).
|Condition or disease|
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||400 participants|
|Target Follow-Up Duration:||1 Day|
|Study Start Date :||December 2012|
|Actual Primary Completion Date :||September 2013|
|Actual Study Completion Date :||September 2013|
- venous thromboembolism [ Time Frame: 1 week ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01744431
|Emek medical center|
|Principal Investigator:||mazen elias, MD||Emek Medical Center|